Hayflick Susan J, Westaway Shawn K, Levinson Barbara, Zhou Bing, Johnson Monique A, Ching Katherine H L, Gitschier Jane
Department of Molecular and Medical Genetics, School of Medicine, Oregon Health and Science University, Portland, OR 97201-3098, USA.
N Engl J Med. 2003 Jan 2;348(1):33-40. doi: 10.1056/NEJMoa020817.
Hallervorden-Spatz syndrome is an autosomal recessive disorder characterized by dystonia, parkinsonism, and iron accumulation in the brain. Many patients with this disease have mutations in the gene encoding pantothenate kinase 2 (PANK2); these patients are said to have pantothenate kinase-associated neurodegeneration. In this study, we compared the clinical and radiographic features of patients with Hallervorden-Spatz syndrome with and without mutations in PANK2.
One hundred twenty-three patients from 98 families with a diagnosis of Hallervorden-Spatz syndrome were classified on the basis of clinical assessment as having classic disease (characterized by early onset with rapid progression) or atypical disease (later onset with slow progression). Their genomic DNA was sequenced for PANK2 mutations.
All patients with classic Hallervorden-Spatz syndrome and one third of those with atypical disease had PANK2 mutations. Whereas almost all mutations in patients with atypical disease led to amino acid changes, those in patients with classic disease more often resulted in predicted protein truncation. Patients with atypical disease who had PANK2 mutations were more likely to have prominent speech-related and psychiatric symptoms than patients with classic disease or mutation-negative patients with atypical disease. In all patients with pantothenate kinase-associated neurodegeneration, whether classic or atypical, T2-weighted magnetic resonance imaging (MRI) of the brain showed a specific pattern of hyperintensity within the hypointense medial globus pallidus. This pattern was not seen in any patients without mutations.
PANK2 mutations are associated with all cases of classic Hallervorden-Spatz syndrome and one third of cases of atypical disease. A specific MRI pattern distinguishes patients with PANK2 mutations. Predicted levels of pantothenate kinase 2 protein correlate with the severity of disease.
哈勒沃登 - 施帕茨综合征是一种常染色体隐性疾病,其特征为肌张力障碍、帕金森症以及脑部铁蓄积。许多患有该疾病的患者在编码泛酸激酶2(PANK2)的基因中存在突变;这些患者被认为患有泛酸激酶相关神经变性病。在本研究中,我们比较了有和没有PANK2突变的哈勒沃登 - 施帕茨综合征患者的临床和影像学特征。
来自98个家庭的123例被诊断为哈勒沃登 - 施帕茨综合征的患者,根据临床评估分为患有典型疾病(特征为起病早且进展迅速)或非典型疾病(起病晚且进展缓慢)。对他们的基因组DNA进行PANK2突变测序。
所有典型哈勒沃登 - 施帕茨综合征患者以及三分之一的非典型疾病患者存在PANK2突变。非典型疾病患者的几乎所有突变都会导致氨基酸变化,而典型疾病患者的突变更常导致预测的蛋白质截短。与典型疾病患者或非典型疾病且无突变的患者相比,有PANK2突变的非典型疾病患者更有可能出现突出的言语相关和精神症状。在所有泛酸激酶相关神经变性病患者中,无论典型或非典型,脑部的T2加权磁共振成像(MRI)均显示在内侧苍白球低信号区内有特定的高信号模式。在没有突变的任何患者中均未见到这种模式。
PANK2突变与所有典型哈勒沃登 - 施帕茨综合征病例以及三分之一的非典型疾病病例相关。一种特定的MRI模式可区分有PANK2突变的患者。预测的泛酸激酶2蛋白水平与疾病严重程度相关。